Medicines for the Brain Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) LS Honig1 , SN Gomperts2 , JP Taylor3 , ND Prins4 , A Gardner5 , K Blackburn5 , JJ Alam5 , JE Galvin6 1. Columbia University Irving Medical Center – New York, NY (United States); 2. Massachusetts General Hospital – Charlestown, MA (United States); 3. Newcastle University - Newcastle Upon Tyne (United Kingdom); 4. Brain Research Center, Amsterdam (Netherlands); 5. Ce ...

Inducement Grants Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company's Chemistry, Manufacturing, and Cont ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEWSWIRE ...